Ross Selby

Real-world evidence use in assessments of cancer drugs by NICE

Ash Bullement, Tanja Podkonjak, Mark Robinson et al. · International Journal of Technology Assessment in Health Care · 2020 · 43 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +17

Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom

Michele Wilson, Annika Bergman, Hélène Chevrou‐Séverac et al. · The European Journal of Health Economics · 2017 · 32 citations

Pharmacy, Pharmacoeconomics, Pharmacotherapy +10

Cost-effectiveness of vedolizumab compared with conventional therapy for ulcerative colitis patients in the UK

Michele Wilson, Ismail Azzabi Zouraq, Hélène Chevrou‐Séverac et al. · ClinicoEconomics and Outcomes Research · 2017 · 18 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17

Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland

Christopher Parker, Beth Woods, James Eaton et al. · Journal of Medical Economics · 2016 · 11 citations

Medicine, Oncology, Pharmacoeconomics +16